Recycling the purpose of old drugs to treat ovarian cancer
| Autor: | Miguel Henriques Abreu, Mariana Nunes, Carla Bartosch, Sara Ricardo |
|---|---|
| Přispěvatelé: | Instituto de Investigação e Inovação em Saúde |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Drug repurposing Review Ex vivo cultures lcsh:Chemistry Efficacy Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Metformin / therapeutic use lcsh:QH301-705.5 Spectroscopy media_common Ovarian Neoplasms / drug therapy Ovarian Neoplasms drug repurposing Diphosphonates chemoresistance General Medicine Metformin Computer Science Applications ex vivo cultures Drug repositioning ovarian cancer Female Itraconazole Chemoresistance medicine.drug Drug medicine.medical_specialty Bevacizumab media_common.quotation_subject Ritonavir / therapeutic use Catalysis Inorganic Chemistry Ovarian Neoplasms / pathology Ovarian cancer Internal medicine medicine Humans Physical and Theoretical Chemistry Molecular Biology Neoplasm Recurrence Local / prevention & control Ivermectin Ritonavir business.industry Ivermectin / therapeutic use Organic Chemistry Drug Repositioning medicine.disease lcsh:Biology (General) lcsh:QD1-999 Diphosphonates / therapeutic use Drug Repositioning / methods Hydroxymethylglutaryl-CoA Reductase Inhibitors Neoplasm Recurrence Local Itraconazole / therapeutic use business |
| Zdroj: | International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 21, Iss 7768, p 7768 (2020) |
| Popis: | The main challenge in ovarian cancer treatment is the management of recurrences. Facing this scenario, therapy selection is based on multiple factors to define the best treatment sequence. Target therapies, such as bevacizumab and polymerase (PARP) inhibitors, improved patient survival. However, despite their achievements, ovarian cancer survival remains poor; these therapeutic options are highly costly and can be associated with potential side effects. Recently, it has been shown that the combination of repurposed, conventional, chemotherapeutic drugs could be an alternative, presenting good patient outcomes with few side effects and low costs for healthcare institutions. The main aim of this review is to strengthen the importance of repurposed drugs as therapeutic alternatives, and to propose an in vitro model to assess the therapeutic value. Herein, we compiled the current knowledge on the most promising non-oncological drugs for ovarian cancer treatment, focusing on statins, metformin, bisphosphonates, ivermectin, itraconazole, and ritonavir. We discuss the primary drug use, anticancer mechanisms, and applicability in ovarian cancer. Finally, we propose the use of these therapies to perform drug efficacy tests in ovarian cancer ex vivo cultures. This personalized testing approach could be crucial to validate the existing evidences supporting the use of repurposed drugs for ovarian cancer treatment. Funding: This manuscript was funded by HOPE: Improving ovarian cancer patients’ survival—donation from an ovarian cancer patient and by the FCT (Fundação para a Ciência e a Tecnologia) project PTDC/MEC-ONC/29503/2017. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|